Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.verified

REGN

Price:

$1007.92

Market Cap:

$109.28B

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carci...[Read more]

Industry

Biotechnology

IPO Date

1991-04-02

Stock Exchange

NASDAQ

Ticker

REGN

The PE Ratio as of October 2024 (TTM) for Regeneron Pharmaceuticals, Inc. (REGN) is 26.70

According to Regeneron Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 26.70. This represents a change of 8.97% compared to the average of 24.50 of the last 4 quarters.

Regeneron Pharmaceuticals, Inc. (REGN) Historical PE Ratio (quarterly & annually)

How has REGN PE Ratio performed in the past?

The mean historical PE Ratio of Regeneron Pharmaceuticals, Inc. over the last ten years is 41.75. The current 26.70 PE Ratio has changed 6.29% with respect to the historical average. Over the past ten years (40 quarters), REGN's PE Ratio was at its highest in in the March 2015 quarter at 170.03. The PE Ratio was at its lowest in in the June 2021 quarter at 4.99.

Quarterly (TTM)
Annual

Average

41.75

Median

21.54

Minimum

8.27

Maximum

133.67

Regeneron Pharmaceuticals, Inc. (REGN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Regeneron Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 115.47%

Maximum Annual PE Ratio = 133.67

Minimum Annual Increase = -51.75%

Minimum Annual PE Ratio = 8.27

Quarterly (TTM)
Annual
YearPE RatioChange
202323.7033.08%
202217.81115.47%
20218.27-44.13%
202014.80-23.65%
201919.3810.48%
201817.54-51.75%
201736.36-23.70%
201647.65-51.55%
201598.35-26.43%
2014133.6785.30%

Regeneron Pharmaceuticals, Inc. (REGN) Average PE Ratio

How has REGN PE Ratio performed in the past?

The current PE Ratio of Regeneron Pharmaceuticals, Inc. (REGN) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

3-year avg

16.59

5-year avg

16.79

10-year avg

41.75

Regeneron Pharmaceuticals, Inc. (REGN) PE Ratio vs. Peers

How is REGN’s PE Ratio compared to its peers?

Regeneron Pharmaceuticals, Inc.’s PE Ratio is greater than CRISPR Therapeutics AG (-14.99), less than Novo Nordisk A/S (40.39), less than Sarepta Therapeutics, Inc. (249.31), greater than Intellia Therapeutics, Inc. (-3.49), less than Incyte Corporation (147.66), greater than Alnylam Pharmaceuticals, Inc. (-488.32), greater than United Therapeutics Corporation (14.78), greater than Ultragenyx Pharmaceutical Inc. (-7.96), greater than Apellis Pharmaceuticals, Inc. (-9.89), greater than PTC Therapeutics, Inc. (-6.21), greater than Reata Pharmaceuticals, Inc. (-89.36), greater than Intercept Pharmaceuticals, Inc. (-13.55), less than Krystal Biotech, Inc. (48.03), greater than Madrigal Pharmaceuticals, Inc. (-9.02), greater than BeiGene, Ltd. (-47.00), less than BioMarin Pharmaceutical Inc. (52.01), greater than ImmunoGen, Inc. (-122.93), greater than Prometheus Biosciences, Inc. (-81.93), greater than Arrowhead Pharmaceuticals, Inc. (-4.14), greater than Ionis Pharmaceuticals, Inc. (-15.37),

Build a custom stock screener for Regeneron Pharmaceuticals, Inc. (REGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Regeneron Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Regeneron Pharmaceuticals, Inc. (REGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Regeneron Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Regeneron Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Regeneron Pharmaceuticals, Inc. (REGN)?

What is the highest PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

What is the 3-year average PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

What is the 5-year average PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

How does the current PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN) compare to its historical average?